| Application number | Title of the application | Filing Date | Status |
|---|
Array
(
[id] => 6639236
[patent_doc_number] => 20030212019
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2003-11-13
[patent_title] => 'Antisense modulation of cot oncogene expression'
[patent_app_type] => new
[patent_app_number] => 10/181873
[patent_app_country] => US
[patent_app_date] => 2002-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23148
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0212/20030212019.pdf
[firstpage_image] =>[orig_patent_app_number] => 10181873
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/181873 | Antisense modulation of cot oncogene expression | Dec 12, 2002 | Abandoned |
Array
(
[id] => 7403629
[patent_doc_number] => 20040023906
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2004-02-05
[patent_title] => 'Antisense modulation of phosphotyrosyl phosphatase activator expression'
[patent_app_type] => new
[patent_app_number] => 10/211179
[patent_app_country] => US
[patent_app_date] => 2002-08-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31638
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0023/20040023906.pdf
[firstpage_image] =>[orig_patent_app_number] => 10211179
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/211179 | Antisense modulation of phosphotyrosyl phosphatase activator expression | Jul 31, 2002 | Abandoned |
| 60/509044 | Method for prevention and treatment of diseases or disorders related to excessive formation of vascular tissue or blood vessels | Jun 26, 2002 | Pending |
Array
(
[id] => 6843622
[patent_doc_number] => 20030148969
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2003-08-07
[patent_title] => 'Antisense modulation of mucin 1, transmembrane expression'
[patent_app_type] => new
[patent_app_number] => 10/029517
[patent_app_country] => US
[patent_app_date] => 2001-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30355
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0148/20030148969.pdf
[firstpage_image] =>[orig_patent_app_number] => 10029517
[rel_patent_id] =>[rel_patent_doc_number] =>) 10/029517 | Antisense modulation of mucin 1, transmembrane expression | Dec 19, 2001 | Issued |
| 10/003126 | Antisense modulation of G protein-coupled receptor ETBR-LP-2 expression | Dec 5, 2001 | Abandoned |
Array
(
[id] => 5908076
[patent_doc_number] => 20020142983
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2002-10-03
[patent_title] => 'MUC-1 antagonists and methods of treating immune disorders'
[patent_app_type] => new
[patent_app_number] => 09/984183
[patent_app_country] => US
[patent_app_date] => 2001-10-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 14512
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0142/20020142983.pdf
[firstpage_image] =>[orig_patent_app_number] => 09984183
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/984183 | MUC-1 antagonists and methods of treating immune disorders | Oct 28, 2001 | Abandoned |
Array
(
[id] => 5921687
[patent_doc_number] => 20020115120
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2002-08-22
[patent_title] => 'Novel molecules of the HKID-1-related protein family and uses thereof'
[patent_app_type] => new
[patent_app_number] => 09/971791
[patent_app_country] => US
[patent_app_date] => 2001-10-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 34080
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0115/20020115120.pdf
[firstpage_image] =>[orig_patent_app_number] => 09971791
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/971791 | Novel molecules of the HKID-1-related protein family and uses thereof | Oct 3, 2001 | Abandoned |
Array
(
[id] => 5936572
[patent_doc_number] => 20020061843
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2002-05-23
[patent_title] => 'Use of mCRP for delivery of materials into cells'
[patent_app_type] => new
[patent_app_number] => 09/971100
[patent_app_country] => US
[patent_app_date] => 2001-10-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 7617
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0061/20020061843.pdf
[firstpage_image] =>[orig_patent_app_number] => 09971100
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/971100 | Use of mCRP for delivery of materials into cells | Oct 2, 2001 | Abandoned |
Array
(
[id] => 6861642
[patent_doc_number] => 20030092650
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2003-05-15
[patent_title] => 'Antisense modulation of sphingosine-1-phosphate lyase expression'
[patent_app_type] => new
[patent_app_number] => 09/967669
[patent_app_country] => US
[patent_app_date] => 2001-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25243
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0092/20030092650.pdf
[firstpage_image] =>[orig_patent_app_number] => 09967669
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/967669 | Antisense modulation of sphingosine-1-phosphate lyase expression | Sep 27, 2001 | Issued |
Array
(
[id] => 6861641
[patent_doc_number] => 20030092649
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2003-05-15
[patent_title] => 'Antisense modulation of vascular endothelial growth factor receptor-2 expression'
[patent_app_type] => new
[patent_app_number] => 09/967655
[patent_app_country] => US
[patent_app_date] => 2001-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28478
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0092/20030092649.pdf
[firstpage_image] =>[orig_patent_app_number] => 09967655
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/967655 | Antisense modulation of vascular endothelial growth factor receptor-2 expression | Sep 27, 2001 | Issued |
Array
(
[id] => 1231195
[patent_doc_number] => 06692959
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2004-02-17
[patent_title] => 'Antisense modulation of IL-1 receptor-associated kinase-4 expression'
[patent_app_type] => B2
[patent_app_number] => 09/966451
[patent_app_country] => US
[patent_app_date] => 2001-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29433
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 205
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/692/06692959.pdf
[firstpage_image] =>[orig_patent_app_number] => 09966451
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/966451 | Antisense modulation of IL-1 receptor-associated kinase-4 expression | Sep 27, 2001 | Issued |
Array
(
[id] => 6861640
[patent_doc_number] => 20030092648
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2003-05-15
[patent_title] => 'Antisense modulation of NAC expression'
[patent_app_type] => new
[patent_app_number] => 09/956712
[patent_app_country] => US
[patent_app_date] => 2001-09-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25288
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0092/20030092648.pdf
[firstpage_image] =>[orig_patent_app_number] => 09956712
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/956712 | Antisense modulation of NAC expression | Sep 18, 2001 | Abandoned |
Array
(
[id] => 6433221
[patent_doc_number] => 20020127661
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2002-09-12
[patent_title] => 'Nucleotide sequences coding for the sugA gene'
[patent_app_type] => new
[patent_app_number] => 09/951753
[patent_app_country] => US
[patent_app_date] => 2001-09-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 7338
[patent_no_of_claims] => 35
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 10
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0127/20020127661.pdf
[firstpage_image] =>[orig_patent_app_number] => 09951753
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/951753 | Nucleotide sequences coding for the sugA gene | Sep 13, 2001 | Abandoned |
Array
(
[id] => 6651266
[patent_doc_number] => 20030105036
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2003-06-05
[patent_title] => 'Antisense Inhibition of vascular endothelial growth factor receptor-1 expression'
[patent_app_type] => new
[patent_app_number] => 09/953318
[patent_app_country] => US
[patent_app_date] => 2001-09-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28026
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0105/20030105036.pdf
[firstpage_image] =>[orig_patent_app_number] => 09953318
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/953318 | Antisense inhibition of vascular endothelial growth factor receptor-1 expression | Sep 12, 2001 | Issued |
Array
(
[id] => 1411083
[patent_doc_number] => 06524854
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2003-02-25
[patent_title] => 'Antisense inhibition of PKA regulatory subunit RII alpha expression'
[patent_app_type] => B1
[patent_app_number] => 09/954560
[patent_app_country] => US
[patent_app_date] => 2001-09-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26708
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/524/06524854.pdf
[firstpage_image] =>[orig_patent_app_number] => 09954560
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/954560 | Antisense inhibition of PKA regulatory subunit RII alpha expression | Sep 10, 2001 | Issued |
Array
(
[id] => 6792510
[patent_doc_number] => 20030087854
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2003-05-08
[patent_title] => 'Antisense modulation of fibroblast growth factor receptor 3 expression'
[patent_app_type] => new
[patent_app_number] => 09/953047
[patent_app_country] => US
[patent_app_date] => 2001-09-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 209
[patent_figures_cnt] => 209
[patent_no_of_words] => 26224
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0087/20030087854.pdf
[firstpage_image] =>[orig_patent_app_number] => 09953047
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/953047 | Antisense modulation of fibroblast growth factor receptor 3 expression | Sep 9, 2001 | Abandoned |
Array
(
[id] => 1324455
[patent_doc_number] => 06599502
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2003-07-29
[patent_title] => 'Intracellular delivery vehicles'
[patent_app_type] => B2
[patent_app_number] => 09/949109
[patent_app_country] => US
[patent_app_date] => 2001-09-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 3
[patent_no_of_words] => 9714
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/599/06599502.pdf
[firstpage_image] =>[orig_patent_app_number] => 09949109
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/949109 | Intracellular delivery vehicles | Sep 6, 2001 | Issued |
Array
(
[id] => 6779183
[patent_doc_number] => 20030050265
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2003-03-13
[patent_title] => 'Antisense modulation of transforming growth factor-beta expression'
[patent_app_type] => new
[patent_app_number] => 09/948002
[patent_app_country] => US
[patent_app_date] => 2001-09-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 19967
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0050/20030050265.pdf
[firstpage_image] =>[orig_patent_app_number] => 09948002
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/948002 | Antisense modulation of transforming growth factor-beta expression | Sep 4, 2001 | Abandoned |
| 09/787169 | Inhibitor of brn-3b and its use for the treatment of breast and ovarian cancer | Aug 23, 2001 | Abandoned |
Array
(
[id] => 1197350
[patent_doc_number] => 06727355
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2004-04-27
[patent_title] => 'Pharmaceutical composition for treatment of Duchenne muscular dystrophy'
[patent_app_type] => B2
[patent_app_number] => 09/930251
[patent_app_country] => US
[patent_app_date] => 2001-08-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10869
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/727/06727355.pdf
[firstpage_image] =>[orig_patent_app_number] => 09930251
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/930251 | Pharmaceutical composition for treatment of Duchenne muscular dystrophy | Aug 15, 2001 | Issued |
